According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
Other analysts have also issued reports about the company. BidaskClub lowered GRIFOLS S A/S from a strong-buy rating to a buy rating in a research report on Tuesday, August 20th. ValuEngine lowered GRIFOLS S A/S from a hold rating to a sell rating in a research report on Thursday, August 1st. Finally, JPMorgan Chase & Co. upgraded GRIFOLS S A/S from a neutral rating to an overweight rating and lifted their price objective for the stock from $21.00 to $22.50 in a research report on Thursday, June 27th. Three analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $20.75.
A number of institutional investors and hedge funds have recently modified their holdings of GRFS. Mackenzie Financial Corp bought a new stake in GRIFOLS S A/S in the 2nd quarter valued at approximately $16,929,000. Royal Bank of Canada lifted its stake in GRIFOLS S A/S by 6.2% in the 2nd quarter. Royal Bank of Canada now owns 190,316 shares of the biotechnology company’s stock valued at $4,016,000 after acquiring an additional 11,128 shares in the last quarter. UBS Group AG lifted its stake in GRIFOLS S A/S by 27.0% in the 2nd quarter. UBS Group AG now owns 1,322,161 shares of the biotechnology company’s stock valued at $27,898,000 after acquiring an additional 280,695 shares in the last quarter. Nuveen Asset Management LLC bought a new stake in GRIFOLS S A/S in the 2nd quarter valued at approximately $1,854,000. Finally, OneAscent Financial Services LLC bought a new stake in GRIFOLS S A/S in the 2nd quarter valued at approximately $312,000. Hedge funds and other institutional investors own 18.00% of the company’s stock.
GRIFOLS S A/S Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
See Also: What is a CD ladder?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.